• Explore /
  • Poster
  • / A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).

Abstract Poster

Authors

null

Joyce F. Liu

Dana-Farber Cancer Institute, Boston, MA

Joyce F. Liu , William Thomas Barry , Robert Michael Wenham , Andrea Elisabeth Wahner Hendrickson , Deborah Kay Armstrong , Nancy Chan , David E. Cohn , Jung-min Lee , Richard T. Penson , Mihaela C. Cristea , James L. Abbruzzese , KOJI MATSUO , Alexander Olawaiye , Sarah Farooq , Elizabeth M. Swisher , Eliezer Mendel Van Allen , Geoffrey Shapiro , Elise C. Kohn , S. Percy Ivy , Ursula A. Matulonis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02345265

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5519)

DOI

10.1200/JCO.2018.36.15_suppl.5519

Abstract #

5519

Poster Bd #

246

Abstract Disclosures

Similar Posters

First Author: Joyce F. Liu

First Author: Jung-min Lee

First Author: B.J. Rimel

First Author: Helen Mackay